Companies / Neuvasq Biotechnologies
Neuvasq Biotechnologies
Company
Neuvasq Biotechnologies is pioneering the development of first-in-class Gpr124- and Reck-targeting Wnt surrogate antibodies, designed to restore the integrity of the blood-retina and blood-brain barriers
Neuvasq Biotechnologies has 1 investor on file, among them Newton Biocapital. Its site was last checked 6 Nov 2026: site answers.
Investors
1 investor on file| Investor | Evidence | Type |
|---|---|---|
| Portfolio page | Venture capital |
More from Newton Biocapital
13 companies on its checked portfolioIts portfolio leans to Healthcare & Biotech (100%).
See Newton Biocapital's full profile · Who invests alongside it
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get Neuvasq Biotechnologies and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when Newton Biocapital adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/neuvasq.com/investors
# also
GET /v1/companies/neuvasq.com
GET /v1/companies/neuvasq.com/news